TRK Inhibition Continues to Advance the Lung Cancer Field
Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
Luis E. Raez, MD, the medical director and chief scientific officer at Memorial Cancer Institute, Memorial Health Care System, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
NTRK fusions are a relatively new target in the lung cancer space, says Raez. Despite their novelty, NTRK fusions are important because they are changing the face of cancer treatment. The reach of NTRK fusions spans 18 different adult and pediatric cancers, he explains.
The original data around the TRK inhibitor, larotrectinib (Vitrakvi) showed that patients will respond to TRK inhibition. This research was revolutionary for lung cancers and other solid tumors because it further solidified the role of genetic testing and targeted therapy for these patient groups.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
